COSMIC-312

Name No. For Patients with Purpose
COSMIC-312 20-05

Adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy

The primary aim of this study is to evaluate the effect of cabozantinib in combination with atezolizumab on the duration of progression-free survival (PFS) and duration of overall survival (OS) versus sorafenib.
The secondary aim is to evaluate the activity of single-agent cabozantinib compared with sorafenib in this patient population.


MK7902-002/E7080-G000-311/LEAP-002

Name No. For Patients with Purpose
MK7902-002/E7080-G000-311/LEAP-002 CTRIAL-IE 18-43

This study will evaluate the safety and efficacy of lenvatinib alone or in combination with pembrolizumab as first-line intervention


Astellas 8951-CL-5201

Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM)


Paricalcitol Trial

Name No. For Patients with Purpose
Paricalcitol Trial 19-33

Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma.

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.


MK3475-966-00

Name No. For Patients with Purpose
MK3475-966-00 19-23

1L Advanced/Unresectable Biliary Tract Carcinoma

The purpose of this study is to compare Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma


FIDES-01 (Formerly ARQ 087-301)

Name No. For Patients with Purpose
FIDES-01 (Formerly ARQ 087-301) 18-10

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.


INCB 54828-302

Name No. For Patients with Purpose
INCB 54828-302 18-45

Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

The purpose of this trial is to evaluate the efficacy of pemigatinib versus standard chemotherapy in the first-line treatment of patients with Unresectable or Metastatic Cholangiocarcinoma, whos tumors harbor FGFR2 gene rearrangement.


Lithium

Name No. For Patients with Purpose
Lithium 11-32

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.


MK3475-937 (KEYNOTE-937)

Name No. For Patients with Purpose
MK3475-937 (KEYNOTE-937) 19-07

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).


SOLSTICE

Name No. For Patients with Purpose
SOLSTICE CTRIAL-IE 19-08

Metastatic colorectal cancer (bowel cancer) that is unresectable and not suitable for intensive therapy

The main purpose of the study is to determine if S95005 in combination with bevacizumab is better than capecitabine with bevacizumab for progression free survival in mCRC patients who have not received any treatment for metastatic disease yet and are not suitable for intensive chemotherapy